• News
  • Podcast
  • Biotech Bulletin
  • Careers
TALG®
  • About
  • Our Team
  • Practice Areas
  • Industries Served
  • Contact
Select Page
Artificial Intelligence and the Implications for Drug Manufacturers (FDA Discussion)

Artificial Intelligence and the Implications for Drug Manufacturers (FDA Discussion)

by Ismail Amin | Mar 6, 2023 | artificial intelligence, Biotech Bulletin, Business Law, Healthcare, Life Sciences, News

On March 1, 2023, the FDA’s Center for Drug Evaluation and Research (CDER) issued a discussion paper on the role of Artificial Intelligence (AI) in the context of drug manufacturing and the implications for “measurement, modeling, and control technologies used in...

Gene Editing & CRISPR Technologies – The Emerging Legal Questions

by Ismail Amin | Feb 24, 2020 | Life Sciences, News

The therapeutic, ethical and legal implications of gene editing and CRISPR technologies are both profound and complex.  However, before we delve into the potential panacea of gene editing technologies, a basic framework and understanding of how it all works is...
  • Facebook
  • Twitter
  • Instagram
  • LinkedIn
© 2023 TALG® • Privacy Policy • Terms & Conditions - The information provided on this site is not legal advice and does not constitute an attorney-client relationship.